title: [Interferon-free treatment for patients with chronic hepatitis C].
abstract: Oral combinations of direct acting antivirals (interferon-free) improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection. In Japanese phase 3 study of daclatasvir plus asunaprevir combination therapy for 24 weeks, 222 patients with chronic HCV genotype 1b infection were enrolled. SVR was achieved by 87% of interferon-ineligible/intolerant patients and 81% of nonresponder patients; rates were similar in cirrhosis (91%) and noncirrhosis (84%) patients, and in patients with IL28B CC (85%) or non-CC (85%) genotypes. The rate of serious adverse events was low among patients. Other oral combination therapies (interferon-free) are ongoing in Japan. Interferon-free all-oral therapy is well tolerated and can achieve a high rate of SVR in patients with HCV genotype 1b.
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Suzuki
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D011759:Pyrrolidines; D013449:Sulfonamides / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D007546:Isoquinolines; D011480:Protease Inhibitors; D011759:Pyrrolidines; D013449:Sulfonamides; D014633:Valine; C549273:daclatasvir; C571889:asunaprevir